Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China. Chen Z, Tang C, Ma X, Tian P, et al. BMC Cancer 2025;25:1216.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen Z, Tang C, Ma X, Tian P, et al. Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China. BMC Cancer 2025;25:1216.
PMID: 40713494